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FAT1 mutations cause a glomerulotubular
nephropathy
Heon Yung Gee1,2,*, Carolin E. Sadowski1,*, Pardeep K. Aggarwal3, Jonathan D. Porath1, Toma A. Yakulov4, Markus Schueler1,
Svjetlana Lovric1, Shazia Ashraf1, Daniela A. Braun1, Jan Halbritter1, Humphrey Fang1, Rannar Airik1, Virginia Vega-Warner5,
Kyeong Jee Cho2, Timothy A. Chan6, Luc G.T. Morris6, Charles ffrench-Constant7, Nicholas Allen8, Helen McNeill9,
Rainer Bu¨scher10, Henriette Kyrieleis11, Michael Wallot11, Ariana Gaspert12, Thomas Kistler13, David V. Milford14,
Moin A. Saleem15, Wee Teik Keng16, Stephen I. Alexander17, Rudolph P. Valentini18, Christoph Licht19, Jun C. Teh19,
Radovan Bogdanovic20, Ania Koziell21, Agnieszka Bierzynska15, Neveen A. Soliman22,23, Edgar A. Otto5,
Richard P. Lifton24,25, Lawrence B. Holzman26, Nicholas E. S. Sibinga27, Gerd Walz4, Alda Tufro3 & Friedhelm Hildebrandt1,25
Steroid-resistant nephrotic syndrome (SRNS) causes 15% of chronic kidney disease (CKD).
Here we show that recessive mutations in FAT1 cause a distinct renal disease entity in four
families with a combination of SRNS, tubular ectasia, haematuria and facultative neurological
involvement. Loss of FAT1 results in decreased cell adhesion and migration in ﬁbroblasts and
podocytes and the decreased migration is partially reversed by a RAC1/CDC42 activator.
Podocyte-speciﬁc deletion of Fat1 in mice induces abnormal glomerular ﬁltration barrier
development, leading to podocyte foot process effacement. Knockdown of Fat1 in renal
tubular cells reduces migration, decreases active RAC1 and CDC42, and induces defects in
lumen formation. Knockdown of fat1 in zebraﬁsh causes pronephric cysts, which is partially
rescued by RAC1/CDC42 activators, conﬁrming a role of the two small GTPases in the
pathogenesis. These ﬁndings provide new insights into the pathogenesis of SRNS and
tubulopathy, linking FAT1 and RAC1/CDC42 to podocyte and tubular cell function.
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ephrotic syndrome (NS) results in proteinuria,
hypoalbuminemia and oedema, and is classiﬁed by its
response to steroid treatment into steroid-sensitive NS
and steroid-resistant NS (SRNS). SRNS leads to chronic kidney
disease (CKD) within a few years of onset, requiring renal
replacement therapy for survival. It causes 15% of all end-stage
kidney disease that manifests by 25 years of age1. SRNS is
considered one of the most intractable kidney diseases, because it
has a 30% risk of recurrence after renal transplant if SRNS is
idiopathic. However, in SRNS with a monogenic cause the risk of
recurrence is reduced from 35 to 8% (ref. 2). Histologically, SRNS
manifests as ‘focal segmental glomerulosclerosis’ (FSGS) or as the
early-onset developmental variant ‘diffuse mesangial sclerosis’
(DMS)3. The ﬁrst insights into the pathogenesis of SRNS were
gained by the discovery of single-gene (monogenic) causes of
SRNS, revealing that the encoded proteins are essential for the
function of the glomerular podocyte4,5. Podocytes are neuron-like
cells that extend multiple tubulin-based primary processes that
branch into secondary actin-based foot processes. Foot processes
interdigitate with those of neighbouring podocytes, forming
between them the glomerular slit diaphragm, which is critical for
the ﬁltering process. Loss of foot process and slit membrane
integrity causes glomerular protein leakage and SRNS.
Advances in molecular diagnostics enables identiﬁcation of the
primary cause of disease in a large fraction of individuals with
SRNS. In a worldwide cohort of 1,783 families, a monogenic
cause of SRNS was detected in 1 of 27 genes in B30% of SRNS
cases manifesting before age 25 years6. Gene identiﬁcation also
enables disease modelling in cell-based and animal models of
gene knockdown or knockout, facilitates screening for small
molecule therapeutics and permits an aetiologic classiﬁcation of
SRNS for therapeutic trials.
Identiﬁcation of monogenic causes of SRNS has revealed that
the encoded proteins are part of protein–protein interaction
complexes that functionally participate in distinct cellular tasks
and signalling pathways within podocytes, including:
(i) Podocyte slit membrane signalling (NPHS1, NPHS2,
CD2AP, PLCE1)7–10,
(ii) Actin-binding complexes within the foot process actin
network (ACTN4, INF2, MYO1E and ANLN)11–14,
(iii) Actin regulation by RHO/RAC/CDC42 (ARHGAP24,
ARHGDIA, KANK1 and 2)15–17,
(iv) Integrin/laminin signalling in podocyte focal adhesions at
the basement membrane (LAMB2 and ITGA3)18–21,
(v) Coenzyme Q10 biosynthesis components (COQ2, COQ6,
PDSS2 and ADCK4)22–25,
(vi) Transcription factors expressed in podocytes (WT1 and
SMARCAL1)21,26, as well as
(vii) Calcium signalling (TRPC6)27,28 and caveolin signalling
(EMP2)29.
Although disease mechanisms of SRNS are not well-under-
stood, altered podocyte cell-migration rate represents a relevant
assay of pathogenicity for most SRNS disease-causing alleles16,30.
Actin remodelling by members of the ‘RHO family of small
GTPases’ RHOA, RAC1 and CDC42 (henceforth ‘RHO
GTPases’) regulates podocyte cell-migration rate30.
Because genetic mapping data indicate a multitude of
additional loci-bearing mutations that might cause monogenic
forms of SRNS, here we perform homozygosity mapping (HM)
and whole-exome sequencing to identify novel monogenic SRNS
genes. We identify mutations in FAT1 that cause a human
glomerulotubular disease with features of both SRNS and tubular
ectasia. Knockdown of Fat1 in renal tubular epithelial cells
decreases cell–cell adhesion, cell migration and activity of small
RHO-like GTPases RAC1 and CDC42, but also induces defects in
the formation of the tubular cell lumen. Podocyte-speciﬁc Fat1
loss-of-function recapitulates the NS phenotype in a mouse
model. Furthermore, knockdown of fat1 in zebraﬁsh causes
formation of pronephric cysts, which is partially rescued by
RAC1/CDC42 activators, conﬁrming a role of the two small
GTPases in the pathogenesis of this renal disease.
Identiﬁcation of this new glomerulotubular disease entity
demonstrates that FAT1 is necessary for glomerular as well as
tubular function. These ﬁndings provide new insights into the
pathogenesis and therapeutic approaches for SRNS and tubular
ectasia, and link FAT1 and RAC1/CDC42 to podocyte and
tubular cell function.
Results
FAT1 mutations cause a glomerulotubular nephropathy.
We previously showed that a causal mutation in 1 of 27 different
single genes can be identiﬁed in B30% of cases with SRNS that
manifest before 25 years of age31. However, genetic mapping data
strongly suggest a multitude of additional monogenic causes of
SRNS32. The ﬁnding that mutations in identiﬁed monogenic
SRNS genes are very rare (LAMB2 (refs 19,33), PLCE1 (ref. 10)
and COQ6 (ref. 23) highlights the need to identify additional
single-gene causes of SRNS in single affected families. To
overcome this limitation, we combined whole exome
sequencing (WES) with HM32,34–36.
A4623, a Turkish boy from consanguineous parents, was
diagnosed with intellectual disability, pulmonary artery stenosis
and bilateral blepharoptosis in early childhood. Magnetic
resonance imaging showed pachygyria and Virchow–Robin
spaces. He was admitted to the hospital at the age of 15 years
because of proteinuria and haematuria. Kidney biopsy showed a
glomerulotubular nephropathy. Typical features of SRNS,
including glomerular podocyte foot process effacement
(Fig. 1a), were seen together with tubular dilation, tubulointer-
stitial inﬁltrations and irregular tubular basement membranes
(Fig. 1b). We performed HM in A4623. HM yielded 13 regions of
homozygosity by descent that represents candidate regions for a
recessive disease gene (Fig. 1g) (ref. 32). Following WES and
ﬁltering of variants from normal reference sequence, three rare
variants in FAT1, PIDD and DZIP1 remained (Supplementary
Table 1) in A4623. Mutations in the 27 known SRNS genes were
excluded by evaluation of the WES data. The variant in the FAT1
gene, which encodes the FAT atypical cadherin 1, is a
homozygous protein truncating mutation (p.P1032Cfs*11)
(Table 1, Fig. 1h–j and Supplementary Table 1).
One child of Arab origin (A3027) presented with proteinuria
and haematuria, and renal ultrasound showed increased
echogenicity (Supplementary Fig. 1). A3027 was diagnosed with
Ewing sarcoma, and lung and spinal metastasis at the age of 15
years. He rapidly progressed to renal failure and despite
radiotherapy, chemotherapy and haemodialysis he died at the
age of 19 years. Because of the rapid onset of renal failure, kidney
biopsy was not performed but ultrasound showed echogenicity
and urine analysis showed haematuria and proteinuria. There was
no other affected individual in the family. HM of this individual
yielded segments of homozygosity by descent with a cumulative
genomic length of 215Mb (Supplementary Table 1). Following
variant ﬁltering by HM and WES, two rare missense variants in
FAT1 and EHD1 remained (Supplementary Table 1). Mutations
in the 27 known SRNS genes were excluded by evaluation
of the WES data. The variant (c.857A4F;p.N286S) in FAT1 is
reported as a SNP in the dbSNP database, however, its minor
allele frequency is 0.0002 and it never occurred in the
homozygous state (Table 1 and Fig. 1h–j). The FAT1 variant
alters an amino-acid residue conserved throughout evolution
down to Drosophila melanogaster (Table 1).
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When performing highly parallel sequencing37 of all FAT1
exons in 1,500 additional individuals with features of NS and 800
individuals with features of tubulointerstitial nephroapathy, we
detected in 2 additional families 4 different recessive (biallelic)
mutations of FAT1 (Table 1, Fig. 1j). In a female
African-American girl (A789) from non-consanguineous
parents, another compound-heterozygous mutation was
detected (c.3008C4T, p.A1003V and c.9259C4G, p. R3087G).
At the age of 9 years, kidney biopsy revealed minimal change NS.
Urine analysis showed haematuria and proteinuria. After steroid
resistance, cyclosporine A was started. One year after onset of NS,
she was diagnosed with Morbus Hodgkin and chemotherapy was
performed. Further information was not available and segregation
analysis was not performed since the girl was lost for follow-up.
There was no other affected individual in the two families. A3507,
an African girl from non-consanguineous parents, showed
haematuria and proteinuria at the age of 2 years. Kidney biopsy
revealed DMS at the age of 2 years and she received unilateral
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Figure 1 | FAT1 mutations cause a glomerulotubular nephropathy. (a) Electron microscopy in A4623 with FAT1 mutation demonstrates the nephrotic
syndrome (NS) feature of foot process effacement (arrowheads). Scale bar, 5 mm. (b) Renal histology of individual A4623 exhibits cystic dilation of renal
tubules (hash), interstitial inﬁltrations (asterisks), and tubular basement membrane disruptions (arrowheads). Scale bar, 100 mm. (c) In A3507 with FAT1
mutation electron microscopy reveals the NS feature of extensive foot process effacement with microvilli formation (arrowheads). Scale bar, 5 mm.
(d) Renal ultrasound of individual A3507 demonstrates loss of corticomedullary differentiation and increased echogenicity (L, liver). (e) Electron
microscopy of A789 shows foot process effacement (arrowheads). Scale bar, 5 mm. (f) Renal histology of A789 shows tubulointerstitial inﬁltrates. Scale
bar, 100mm. (g) Homozygosity mapping identiﬁed 13 recessive candidate loci in individual A4623 with NS and tubular ectasia (TE). Non-parametric lod
scores (NPL) were calculated and plotted across the human genome. The x-axis shows Affymetrix 250K StyI array SNP positions on human chromosomes
concatenated from p-ter (left) to q-ter (right). Genetic distance is given in cM. 13 maximum NPL peaks (red circles) indicate candidate regions of
homozygosity by descent. The FAT1 locus (arrowhead) is positioned within the maximum NPL peak on chromosome 4q. (h) Exon structure of human FAT1
cDNA. FAT1 contains 27 exons. Positions of start codon (ATG) and of stop codon (TGA) are indicated. (i) Domain structure of FAT1. Protein domains are
depicted by coloured bars in relation to encoding exon positions (h). FAT1 contains 33 cadherin domains (CA), a laminin G domain (LamG) and ﬁve
epidermal growth factor (EGF)-like repeat domains (green bullets) in its extracellular region, followed by a transmembrane region (light blue bar) and a
C-terminal cytoplasmic domain containing a PTB-like motif (red bar) with a PDZ-binding motif (-HTEV). (j) Two homozygous (H) and four different
compound-heterozygous FAT1 mutations (h) detected in four families with a glomerulotubular nephropathy. Family numbers (underlined), mutations and
predicted translational changes are indicated (see also Table 1).
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nephrectomy at the age of 2 years. In addition, a mild
hydrocephalus was drained with a ventriculoperitoneal shunt.
One of the compound-heterozygous mutation (c.4517G4A,
p.R1506H) was detected in her mother, but not the other. DNA
from the father was not available.
Three out of four mutations are reported as a SNP in the
dbSNP database, but their allele frequencies are either not
available or very rare (Table 1). For exclusion of known genetic
causes of SRNS, 27 known genes previously linked to SRNS
were screened in these individuals, but no explanatory mutations
were detected6. Interestingly, all affected individuals exhibited a
glomerulotubular nephropathy of SRNS, tubular ectasia and
microscopic haematuria (Fig. 1a–f). In addition, two individuals
had a central nervous system phenotype, including hydrocephalus
and pachygyria (with intellectual disability and bilateral
blepharoptosis) (Table 1, Supplementary Fig. 1).
FAT1 is a member of a small family of vertebrate cadherin-like
genes, designated FAT1–FAT4 in humans, whose orthologues
were ﬁrst recognized in Drosophila38. The FAT1 protein
contains 33 cadherin repeats, followed by 5 epidermal growth
factor (EGF)-like repeat domains, a laminin G domain, a
transmembrane domain and an intracellular domain (Fig. 1i).
FAT cadherins play a role in cell migration, lamellipodia
dynamics, cell polarity and cell–cell adhesion. Fat cadherins have
been reported to interact with Ena/VASP proteins, atrophins,
b-catenin, scribble and HOMER1–HOMER3, thereby inﬂuencing
Wnt and Hippo signalling and the regulation of planar cell
polarity (PCP), the process by which cells become polarized and
organized within the plane of an epithelial sheet. The Fat1 /
mouse displays abnormal podocyte foot processes, brain
developmental defects and eye abnormalities39.
FAT1 defects reduce cell migration and cell–cell adhesion. To
examine if FAT1 mutations cause defects of cellular function, we
obtained ﬁbroblasts from individual A4623. By immunoblotting
of patient ﬁbroblast cellular lysates (Fig. 2a) using an antibody
that recognizes the intracellular domain of FAT1 (ref. 40) (Fig. 1i)
we demonstrated absence of FAT1 protein in ﬁbroblasts of
individual A4623 (Fig. 2a), who carries a homozygous truncating
mutation of FAT1 (p.P1032Cfs*11) (Table 1, Fig. 1j).
To further characterize cellular defects in patient ﬁbroblasts, we
employed a cell-migration assay (Fig. 2b), which has been
previously used to demonstrate deﬁciencies of cell migration rate
in models of multiple monogenic SRNS genes, including
ARHGDIA16, KANK2 (ref. 17), MYO1E13,41, ARHGAP24
(ref. 15) and FAT1 (refs 40,42). We found that ﬁbroblasts from
individual A4623 with a homozygous truncating mutation of
FAT1 p.P1032Cfs*11 exhibited decreased migration rate
(Fig. 2b,c). The decreased migration of ﬁbroblasts from A4623
with FAT1 mutation was partially rescued by RAC/CDC42
activator II, indicating that RHO-like small GTPase activity may
be relevant to the pathogenesis of the disease caused by loss of
FAT1 (Fig. 2b,c). Similarly, knockdown of FAT1 in differentiated
cultured podocytes led to decreased migration rate (Fig. 2d,e and
Supplementary Fig. 2). This effect was likewise mediated by RHO
GTPases, because decreased migration was partially mitigated by
treatment with RAC/CDC42 activator II (Fig. 2d,e). To conﬁrm
whether knockdown of FAT1 affects RHO GTPases, we used
GST–rhotekin to assay the active GTP-bound state of RHOA and
used GST–PAK1 to assay the active states of RAC1 and CDC42.
Knockdown of FAT1 in differentiated podocytes decreased the
active state of RAC1 and CDC42 (Supplementary Fig. 3a,c,d) but
had no effect on RHOA (Supplementary Fig. 3b,e), indicating
RAC1 and CDC42 are more relevant to the pathogenesis of SRNS
caused by loss of FAT1. In addition, overexpression of dominant
negative CDC42 (T17N) decreased cell migration in control
differentiated cultured podocytes, but failed to further decrease
migration in podocytes with FAT1 knockdown, suggesting that
CDC42 is a downstream mediator of FAT1-mediated cell
migration (Supplementary Fig. 4).
We then tested whether there was decreased cell–cell adhesion,
which was recognized previously as a feature of FAT1 loss-of-
function43. We found that ﬁbroblasts from individual A4623 with
the homozygous truncating mutation exhibited decreased
cell–cell adhesion (Fig. 2f). Moreover, speciﬁc knockdown of
FAT1 in differentiated cultured podocytes also impaired cell–cell
adhesion, conﬁrming that this effect is due to loss of FAT1
expression (Fig. 2g).
Podocyte-speciﬁc Fat1 loss-of-function leads to FSGS. In
addition to in vitro cell-based studies, we examined the effect of
Table 1 | Mutations of FAT1 in four families with nephrotic syndrome (NS) and tubular ectasia (TE)
Family-
Individual
Sex Ethnic
origin
Nucleotide
change
Amino-acid
change
Exon
(zygosity,
segregation)
MT PP2* Amino-acid
conservation
Frequencies
in the EVS
databasew
Frequencies in
the dbSNP
databasez
Consanguinity Age of
onset (age
at ESRD)
Renal
manifestation
Extrarenal
manifestations
Biopsy
(at age)
Therapy and
response
A4623 M Turkish c.3093_3096del p.P1032Cfs*11 2 (Hom) NA NA — — — Yes 15 years NS, TE, HU ID, PMG, BP, PAS TIN, MS,
thin GBM
(12 years)
—
A3027 M Arab c.857A4G p.N286S 2 (Hom) DC 0.016 D.r. — rs201488687
MAF¼0.0002
Yes 15 years (15
years)
NS, TE, HU Ewing sarcoma
(15 years) with lung
and spinal metastasis,
RVUR IIIo
ND HD, RT, CHT,
deceased at
19 years
A789 F African-
American
c.3008C4T
c.9259C4T
p.A1003V
p.R3087G
2 (het)
13 (het)
DC
DC
1
0.999
C.e.
C.e.
AA¼0/
AG¼ 1/
GG¼ 6110
AA¼0/
AG¼ 1/
GG¼6,164
rs369363545
(MAF, N/A)
rs375998390
(MAF, N/A)
No 9 years NS, TE, HU Hodgkin lymphoma
(10 years)
MCNS
(9 years)
SR, CsA, CHT
A3507 F African c.4517G4A
c.5671C4A
p.R1506H
p.P1891T
8 (het)
10 (het)
DC
DC
0.494
1.0
C.e.
C.e.
—
TT¼0/
TG¼ 2/
GG¼ 6,048
—
rs185078412
MAF¼0.0006
No 2 months NS, TE, HU Hydrocephalus DMS
(2 years)
Unilateral NE
(2 years)
BP, Bilateral blepharoptosis; C.e., Caenorhabditis elegans; CHT, chemotherapy; CsA, cyclosporin A; DC, disease causing; DMS, diffuse mesangial sclerosis; D.r., Danio rerio; ESRD, end-stage renal disease;
EVS, Exome Variant Server; F, female; FSGS, focal segmental glomerulosclerosis; GBM, glomerular basement membrane; HD, haemodialysis; het, heterozygous; Hom, homozygous; HU, haematuria, ID,
Intellectual disability; m, Maternal; M, male; MCNS, minimal change nephrotic syndrome; mo, month; MS, mesangial sclerosis; MT, mutationtaster; N, no; NA, not applicable; N/A, not available; NE,
nephrectomy; ND, no data; p, paternal; PAS, pulmonary artery stenosis; PMG, pachygyria; PP2, Polyphen Prediction score Humvar; RT, radiotherapy; RVUR, right vesicourethral reﬂux; SR, steroid resistant;
TE, tubular ectasia; TIN, tubular interstitial nephritis; Y, yes.
*Polyphen prediction score HumVar ranges from 0 to 1.0. 0, benign; 1.0, probably damaging.
wExome variant Server (http://evs.gs.washington.edu/EVS/).
zdbSNP database (http://www.ncbi.nlm.nih.gov/SNP).
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Fat1 loss-of-function on glomerular integrity in vivo. Loss of Fat1
in a constitutive Fat1 / mouse model was previously described
to cause perinatal death, features of NS with podocyte foot
process effacement and brain developmental defects39. Thus,
we generated a mouse model of podocyte-speciﬁc loss of
Fat1 function, in which loss of Fat1 is driven by the podocyte
NPHS2/podocin promoter (Pod-Cre) (Supplementary Fig. 5a,b)44.
Podocyte-speciﬁc Fat1 mutants were viable, born in ratios
suggesting no embryonic lethality (n¼ 11 litters, 120 pups).
Mice had no external malformation phenotype and survived
to adulthood (up to 8 months). Newborn podocyte-speciﬁc
Fat1 / mice had normal renal histology, but transmission
electron microscopy (TEM) revealed persistence of cuboidal
podocytes, wide foot processes and tight-junction–like cell
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Figure 2 | Loss of FAT1 causes defects in migration and cell–cell adhesion in ﬁbroblasts and cultured podocytes. (a) Cell lysates from ﬁbroblasts of
individuals A4623 were collected and protein level of FAT1 was analysed by western blotting with FAT1–GST antibody. FAT1–GST antibody recognizes the
intracellular domain of FAT1 (C-terminal 385 aa of mouse FAT1), thus demonstrating the deﬁciency of the truncated FAT1 protein (p.P1032Cfs*11) resulting
from c.3093_3096del FAT1 mutation in A4623. (b) Cell migration assay using the xCELLigence system. Fibroblasts from A4623 show decreased migration
compared with control. Note that the decrease in migration of A4623 ﬁbroblasts was partially rescued by the RAC/CDC42 activator II. Each cell index value
corresponds to the average of more than triplicates and s.d. is in only one direction for clarity. (c) Bar graphs represent the area under curves of b and data
respresent the meanþ s.d. of three independent experiments. *Po0.05, t-test. (d) Effect of FAT1 knockdown on podocyte migration. Differentiated cultured
human podocytes transfected with FAT1 siRNA exhibited decreased migration (red line) compared with scrambled siRNA controls (black line). Decreased
podocyte migration due to FAT1 knockdown was partially rescued by RAC/CDC42 activator II (green line). Each cell index value corresponds to the average of
more than triplicates and s.d. is in only one direction for clarity. (e) Bar graphs represent the area under curves of d and data respresent the meanþ s.d. of
three independent experiments. *Po0.05, t-test. (f) Cell–cell adhesion assay using calcein AM demonstrated that decreased cell–cell adhesion in ﬁbroblasts
from individual A4623 compared with control ﬁbroblasts. Data respresent the mean±s.d. of more than ﬁve independent experiments in f and g. *Po0.05;
t-test. (g) Knockdown of FAT1 by two different siRNAs in differentiated podocytes resulted in decreased cell–cell adhesion in the calcein AM assay.
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junctions in lieu of slit-diaphragms (Supplementary Fig. 5c–k),
conﬁrming that Fat1 is required for normal podocyte foot
process and slit-diaphragm development. Adult podocyte-speciﬁc
Fat1 / mutants developed progressive proteinuria with
massive albuminuria at 4 months of age, B60-fold higher than
control mice, whereas heterozygous Fat1 mutants had only very
mild albuminuria (Fig. 3a,b). However, serum albumin was not
signiﬁcantly different in Fat1 / and control mice (3.2±0.23
versus 3.3±0.15 g dl 1). Histologic examination in homozygous
podocyte-speciﬁc Fat1 / mutants revealed FSGS, with the
presence of protein casts and tubulointerstitial nephropathy,
while only mild mesangial expansion was observed in podocyte-
Fat1 heterozygous mutants (Fig. 3c–f). On ultrastructural
examination by TEM control, Pod-Cre and Fat1f/fsingle
transgenic mice showed normal histology and ultrastructure
(Fig. 3g,h,j), whereas homozygous Fat1 / mutants exhibited
widespread foot process effacement, microvillar transformation
and collapsed F-actin (Fig. 3i,k). Slit-diaphragms are remarkably
decreased in Fat1 / mutants and cell junctions of effaced foot
processes resemble tight junctions (Fig. 3k).
Loss of Fat1 causes CDC42-mediated renal tubular defects.
To examine mechanisms of tubular defects of renal tubule
architecture, we performed transient Fat1 knockdown in mouse
inner medullary collecting duct (IMCD3) cells, a renal tubule cell
line that has broadly been used to study tubular defects35,45. We
found that knockdown of Fat1 perturbed lumen formation of
IMCD3 spheroids (Fig. 4a,b), suggesting that FAT1 is involved in
the regulation of apicobasal polarity. However, this lumen
formation did not result from ciliogenesis because cells with
FAT1 knockdown did not have a problem in ciliation (Fig. 4a).
Similarly, ﬁbroblasts from A4623 with a homozygous truncating
mutation did not show any defect in number or structure of cilia
compared with control ﬁbroblasts (Supplementary Fig. 6),
suggesting that FAT1 is not directly involved in ciliogenesis.
Because ﬁbroblasts of individuals with FAT1 mutation had cell
migration defects (Fig. 2b), and because Fat1 also regulates
cell migration in many different cell types including podocytes,
we examined whether Fat1 also regulates cell migration in
IMCD3 renal tubular cells. We found that knockdown of Fat1
using two different short hairpin RNAs (shRNAs) did in fact
decrease cell migration rate in IMCD3 cells (Fig. 4b,c and
Supplementary Fig. 7a).
Apicobasal cell polarity is controlled by the PCP pathway and
FAT family proteins are involved in this pathway46. FAT family
proteins are upstream PCP proteins, Scribble is one of the PCP
core proteins and RHO GTPases are downstream PCP effector
proteins47. Therefore, we hypothesized that the observed defects
in both lumen formation and cell migration may be mediated by
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Figure 3 | Podocyte-speciﬁc Fat1 deletion causes massive proteinuria and FSGS in adult mice. (a) Urine (5 ml) resolved by SDS–PAGE and stained with
Coomassie blue shows massive albuminuria in podocyte-Fat1 / mutants as quantitated in (b) BSA¼ 1mg bovine serum albumin. The number of mice
studies in a–c were: n¼ 10 (þ /þ , 5 Pod-Cre and 5 Fat1f/f); n¼4 (Pod-Cre:Fat1þ /-); n¼ 5 (Pod-Cre:Fat1 / ). The experimental groups were compared by
analysis of variance. *Po0.05, t-test. (c) On H&E staining, Fat1 / show focal glomerular sclerosis (white arrow) and protein casts (black arrows)
compared with Fat1þ /- (d). (e,f) On PAS staining, Fat1 / kidneys show focal glomerular sclerosis (white arrows), protein casts (black arrows) and
interstitial inﬁltrates (thin arrow). (c–f) Scale bars, 40mm. (g–h) On TEM, Pod-Cre and Fat1f/f single transgenic kidneys show normal glomerular ﬁltration
barrier ultrastructure. (i) Fat1 / kidneys exhibit complete foot process effacement (red arrows), absence of slit-diaphragms and F-actin collapse
in podocytes (black arrows). GBM and endothelium are intact. (j) Fat1þ /þ kidneys show normal glomerular ﬁltration barrier ultrastructure; (k) In
Pod-Cre:Fat1 / , glomeruli tight junctions (red arrows) link the effaced foot processes. Scale bars, 2 mm (g–i); and 1mm (h–k).
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disruption of RHO/RAC/CDC42 signalling. When measuring
active RHOA by a GST–Rhotekin pull-down assay in IMCD3
cells, we found that on knockdown of Fat1active GTP-bound
RHOA was unaltered (Fig. 4e and Supplementary Fig. 7b).
In contrast, when measuring active CDC42 and RAC1 by
GST–PAK1 pull-down assay, we found that on knockdown of
Fat1 active CDC42 and RAC1 were both decreased (Fig. 4f and
Supplementary Fig. 7c,d). These results in IMCD3 cells are
congruent with those in cultured podocytes (Supplementary
Fig. 3) and indicate that CDC42 and RAC1 are more relevant
than RHOA for the pathogenesis of the glomerulotubular disease
that is caused by loss of FAT1.
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Figure 4 | Loss of FAT1 causes a renal tubular phenotype via defective RHO GTPase signalling. (a) IMCD3 cells ciliated apically and formed a spheroid
containing a central lumen (asterisk) when grown in 3D matrigel culture for 3 days; lumens were perturbed on Fat1 knockdown (shRNA#1 and shRNA#3).
Cells were stained for acetylated a-tubulin (red), b-catenin (green) and DAPI (blue). Scale bars, 10mm. (b) Percentage of abnormal spheroids. More than
50 spheroids were examined in each experiment. Data represent the meanþ s.d. of three independent experiments in b,c. *Po0.05, t-test. (c) The effect of
Fat1 knockdown on cell migration. Bar graphs represent the area under curves of d. (d) The effect of Fat1 knockdown on cell migration. Compared with
baseline (dashed black line), addition of serum strongly increases migration rate in IMCD3 cells with scrambled shRNA (Scr) (solid black line). In contrast,
IMCD3 cells stably transfected with Fat1 shRNAs #1 (red continuous line) or #3 (red dashed line) exhibited slower rate of migration. Each cell index value
corresponds to the average of more than triplicates and s.d. is in only one direction for clarity. (e) Active GTP-bound RHOA precipitated from IMCD3. Cells
transfected with scrambled control siRNA versus Fat1 shRNA exhibited no signiﬁcant difference in relative RHOA activity. This is representative of three
experiments. (f) Active GTP-bound CDC42 or RAC1 using a GST–PAK1 (CRIB) pull-down assay. Note that Fat1 knockdown leads to a signiﬁcant decrease in
relative CDC42 and RAC1 (31% and 44%, respectively) compared with Scr control cells. This is representative of four experiments. Quantiﬁcation of e and f
is presented in Supplementary Fig. 7. (g–h) fat1 morpholino-oligonucelotide (MO) was injected to Wt1b::GFP transgenic zebraﬁsh. Zebraﬁsh injected with
control MO did not produce any phenotype. Depletion of fat1 by a fat1 MO targeting the translation initiation site of zebraﬁsh fat1 caused pronephric cysts
(asterisks) in 78 of 325 zebraﬁsh embryos (24%). Scale bars, 100 mm. (i) Activator I (Rho/Rac/Cdc42 activator I) reduced cyst formation to 9.7% (26 of
268 embryos), and activator II (Rac/Cdc42 activator II) to 12.0% (59 of 490 embryos). *Po0.001, w2-test.
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We then studied in vivo the effects on renal tubule cell
architecture that we had observed in cell-based systems in vitro.
We chose zebraﬁsh as a model organism, because zebraﬁsh
embryo is amenable to genetic manipulation such as injection of
morpholino (MO) and knockdown of fat1 in zebraﬁsh is known
to cause pronephric cysts47. We performed MO knockdown of
fat1 in Wt1b::GFP transgenic zebraﬁsh, in which pronephric
kidney cysts can readily be visualized. We found that, whereas
zebraﬁsh injected with control MO did not produce any
phenotype (Fig. 4e), depletion of fat1 caused pronephric cysts
in 24% of zebraﬁsh embryos (Fig. 4f). To further corroborate the
pathogenic role of RAC1/CDC42 signalling, we tested the effect of
two different RHO/RAC/CDC42 activators on rescue of the
zebraﬁsh pronephric renal cystic phenotype. We found that the
chemically distinct Rho GTPase activators I and II reduced cyst
formation from 31% to 9.7% and 12.0%, respectively (Fig. 4i).
Discussion
We here identify recessive mutations of FAT1 as causing a
glomerulotubular nephropathy. Four families with FAT1 muta-
tions presented with a combination of SRNS, tubular ectasia,
haematuria and facultative neurological involvement.
Mechanistically, our studies implicate RHO-like small GTPase
signalling in the pathogenesis of both, the glomerular and the
tubular phenotypes.
In a global Fat1 knockout mice, Fat1 null pups died within 48 h
of birth, which was attributed to abnormal podocyte foot process
fusion with obliteration of the slit membranes39. These ﬁndings
are consistent with the concept that FAT1 provides spacing
between cells in the kidney and plays a role in the formation of
intercellular junctions in the kidney60. While our model of
podocyte-speciﬁc Fat1 deletion caused identical podocyte foot
process fusion at birth, we did not observe perinatal lethality,
suggesting that perinatal lethality with global Fat1 loss reﬂects a
different developmental problem.
Fat1 null mice also exhibited partially penetrant midline
developmental defects including holoprosencephaly, as expected
from strong Fat1 expression within the neuroepithelium.39 This
mouse model is consistent with our ﬁnding of a combined renal
and neurologic disease phenotype in human recessive FAT1
mutation. Our observation of incomplete penetrance of the
neuronal involvement in individuals with FAT1 mutation
parallels the ﬁndings in the mouse model and is most likely
due to compensation by the other FAT proteins (FAT2, 3 or 4)38,
and to the fact that all of the individuals with two recessive
FAT1mutations (except A4623) carried at least one hypomorphic
allele, that is, an allele that is expected not to convey full
loss-of-function (Table 1). It is also consistent with the ﬁnding
that individual A4623, who carries the homozygous truncating
mutation, has a disease phenotype with the most severe neuronal
involvement (Table 1).
Cooperation of different members of FAT cadherins was
demonstrated in mouse models of combined loss-of-function of
Fat4 and Fat1, where FAT proteins cooperate in regulating
multiple aspects of tissue morphogenesis in the kidney and other
organs. Fat function affected renal tubular elongation, neural tube
formation and cochlear morphology via its effects on mechanisms
of PCP. In this context, removal of one copy of the murine Fat1
gene exacerbated the renal tubular cyst phenotype of mice48.
Taken together, our cell-based and in vivo studies using mouse
and zebraﬁsh suggest that the glomerular SRNS-like disease
phenotype results from impaired cell migration of glomerular
podocytes. Indeed, defective podocyte migration is a disease
mechanism common to multiple different monogenic forms of
SRNS30. Likewise, defective cell migration was recently
recognized as a central mechanism of renal tubular
regeneration49. Interestingly, Fat1 knockdown limited migration
of renal tubule cells and also impaired their ability to form
lumens in cultured spheroids, suggesting that also the renal
tubular defect may be mediated by impaired cell migration.
We further demonstrated that RAC1 and CDC42 activity are
impaired in both cultured podocytes and tubular cells with
decreased Fat1 expression, and that activation of these small
GTPases partially corrects defective cellular migration that occur
with Fat1 deﬁciency. This suggests that the pathogenesis of both
the renal glomerular and tubular defects is mediated by decreased
RAC1/CDC42 as a potential unifying mechanism underlying
both the glomerular and tubular disease phenotypes. We conﬁrm
the relevance of this disease mechanism by showing that two
different RAC1/CDC42 activators mitigate the pronephric cyst
phenotype in zebraﬁsh.
Data from human genetics and animal models have shown the
importance of RHO GTPase signalling in CKDs15,16,50–52.
ARHGAP24 or ARHGDIA mutations identiﬁed in human SRNS
cause upregulation of both RAC1 and CDC42 and lead to
increased podocyte migration15,16. This is congruent with the
ﬁnding that active RAC1 (but not RHOA) is upregulated in
Arhgdia / mice. However, CDC42 activity has not been
examined in the Arhgdia / mouse model53. Scott et al.50
showed that podocyte-speciﬁc deletion of CDC42 (but not RHOA
and RAC1) in mice results in foot process effacement and
proteinuria. INF2 mutations also decrease active CDC42 at the
plasma membrane and cause mislocalization of CDC42 within
the cytoplasm52. Therefore, either aberrant activation or
inactivation of CDC42 interferes with podocyte function. In
addition, cdc42 knockdown in zebraﬁsh led to hydrocephalus,
body oedema and pronephric cysts, and kidney tubule-speciﬁc
deletion of CDC42 resulted in renal cysts and renal failure within
weeks of birth51, indicating that CDC42 is also important for
proper tubular function. In this study, we show that the impaired
podocyte migration and the pronephric cysts in fat1-knockdown
zebraﬁsh were partially rescued by a RAC/CDC42 activator,
suggesting that the combined glomerulotubular phenotype
resulting from FAT1 mutations is mediated by decreased RAC1
and CDC42 in both glomeruli and tubules.
Recently Morris et al.43 identiﬁed FAT1 mutations in human
cancers including glioblastoma and colorectal cancer, and showed
that loss of FAT1 leads to aberrant activation of Wnt signalling.
The FAT1 mutations identiﬁed by Morris et al.43 were somatic
and mostly heterozygous. However, in the glomerulotubular
disease described here renal disease resulting from FAT1
mutations is recessive, requiring two mutant alleles, which are
inherited from the heterozygous parents. It is not clear whether
individuals with recessive FAT1 mutations will develop cancer
later in life. However, it is important to note that two individuals
(A3027 and A789) had Ewing sarcoma and Hodgkin’s
lymphoma, respectively (Table 1). How the respective FAT1
mutations identiﬁed in these individuals might contribute to
neoplastic disease will require further focused study.
FAT1 is implicated in Hippo signalling through the interaction
with Scribble and Hippo signalling is required for normal
pronephros development in zebraﬁsh47. Yes-associated protein
(Yap) is a downstream transcriptional effector of Hippo signalling
and is essential for nephron induction and morphogenesis54.
Recently, it was shown that Cdc42 acts upstream of Yap during
development to promote Yap-dependent gene expression and
shape functioning nephrons54. Therefore, it is also conceivable
that the glomerulotubular nephropathy caused by loss of FAT1
may result from defective Hippo signalling due to decreased
Cdc42 activity, which we have shown in this study (Fig. 4f and
Supplementary Fig. 3a).
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Because SRNS causeB15% of all CKD in the ﬁrst two decades
of life6, the balance of RAC1/CDC42 signalling may be a
worthwhile target when developing drugs to prevent ESKD that is
caused by SRNS.
Methods
Study participants. Following informed consent for WES, we obtained clinical
data and blood samples from individuals with SRNS or NPHP from worldwide
sources. Approval for human subjects’ research was obtained from the University
of Michigan and Boston Children’s Hospital Institutional Review Boards and from
relevant local Review Boards. Deposition of WES data in public databases was not
obtained at the time. The diagnosis of NS or NPHP was made by (paediatric)
nephrologists based on standardized clinical and renal histologic criteria55. Renal
biopsies were evaluated by renal pathologists. Clinical data were obtained using a
standardized questionnaire (http://www.renalgenes.org).
Whole exome sequencing. We combined WES with HM as established
previously32,36. For HM32 the ‘Human Mapping 250 k StyI’ array (Affymetrix) was
utilized. Genomic DNA samples were hybridized, and scanned using the
manufacturer’s standard protocol at the University of Michigan Core Facility
(www.michiganmicroarray.com). Non-parametric logarithm of odds (LOD) scores
were calculated using a modiﬁed version of the program GENEHUNTER 2.1 (refs
56,57) through stepwise use of a sliding window with sets of 110 SNPs using the
program ALLEGRO58. Genetic regions of homozygosity by descent (‘homozygosity
peaks’) were plotted across the genome as candidate regions for recessive disease-
causing genes as described32,35. Disease allele frequency was set at 0.0001, and
Caucasian marker allele frequencies were used. Variant burden analysis was
performed as previously described59 using Agilent SureSelect human exome
capture arrays (Life technologies) with next-generation sequencing on an Illumina
sequencing platform. Sequence reads were mapped against the human reference
genome (NCBI build 37/hg19) using CLC Genomics Workbench (version 6.5.1)
software (CLC bio, Aarhus, Denmark). Mutation calling (Supplementary Table 1)
was performed by geneticists/cell biologists, who have knowledge of clinical
phenotypes, pedigree structure, HM and WES evaluation. All the coding exons
of FAT1 were examined by applying a high-throughput mutation analysis method
of microﬂuidic array-based muyltiplex PCR (Fluidigm 48.48 Access Array) and
consecutive barcoded next-generation sequencing (MiSeq, Illumina)37.
Zebraﬁsh maintenance and injections. Approval for zebraﬁsh research was
obtained from the University Committee on the Use and Care of Animals
(UCUCA) of the University of Freiburg. Transgenic wt1b::GFP zebraﬁsh line was
raised and maintained as described60. Fertilized eggs were microinjected with 4 nl
of injection solution at the one-to-two-cell stage with MOs (Gene Tools LLC)
diluted in 200mM KCl, 0.1% Phenol Red (Sigma-Aldrich Corporation) and 10mM
HEPES. zFat1 MO has been previously described47. About 0.5 pmol of zebraﬁsh
p53 MO (50-GCGCCATTGCTTTGCAAGAATTG-30 , Gene Tools) was always
co-injected to reduce the unspeciﬁc effects of the MOs61. About 1.6 pmol zFat1MO
was injected either alone or together with either 1 mgml 1 of Rho/Rac/Cdc42
Activator I or 0.5Uml 1 of Rac/Cdc42 activator II (Cytoskeleton). Scoring of
percentage of cyst formation and zebraﬁsh embryo imaging was done on mixed
male and female embryos at 48 h post fertilization under a Leica MZ16 stereo
microscope (Leica).
Podocyte conditional Fat1-deﬁcient mice. To develop the Fat1 conditional allele
in mice, homologous recombination was used to introduce LoxP sites ﬂanking
exon 2. The targeting construct for the Fat1 locus was generated from a C57/BL6
strain bacterial artiﬁcial chromosome (BAC) clone (Children’s Hospital Oakland
Research Institute) by homologous recombination BAC engineering techniques
(Open Biosystems). All junctions and overall structure were conﬁrmed by
sequencing and long-range PCR. LoxP sites were introduced on each side of
exon 2, which encodes the signal peptide and N-terminal 1,089 aa of Fat1.
The neomycin selection cassette was ﬂanked by Frt sequences for removal by
Flp recombinase.
Electroporation of the linearized construct into WW6 embryonic stem (ES)
cells, followed by selection with G418 and ganciclovir, yielded a high percentage
(B60%) of homologous recombinants. A Fat1þ /loxES clone injected into C57/BL6
blastocysts yielded three highly chimeric mice that transmitted the targeted allele to
offspring. The Frt-ﬂanked neo cassette was removed in a cross with a FLPeR mouse
(129S4/SvJaeSorGt (ROSA) 26Sortm1(FLP1)Dym/J, Jackson Labs). Heterozygous
mice were interbred to generate homozygous conditionally targeted Fat1 mice
(Fat1loxP/loxP) in a mixed 129SV/BL6 genetic background. To delete fat1 selectively
in podocytes, female Fat1þ /ﬂ mice were bred with male podocin-cre mice44 and
double heterozygous were backcrossed to obtain pod-cre:Fat1ﬂ/ﬂ. Podocin-cre mice
were provided by Dr Holzman. All animals were housed in pathogen-free
conditions, and protocols approved by the standing committees of the Albert
Einstein Institute for Animal Studies and the Yale Animal Resources Center.
Urinary albumin was measured using mouse albumin ELISA (Bethyl Laboratories)
and SDS–PAGE/Coomassie Blue staining as previously described62. Plasma and
24 h urine creatinine were measured by HPLC62. Renal morphology was examined
in newborn (1–3-day-old) mice and in 4–8-month-old mice by light microscopy
(haematoxylin and eosin- and periodic acid-Schiff-stained sections) and by TEM
using standard techniques62.
Cell culture and transfection. The immortalized human podocytes63 were kindly
provided by Dr Saleem (the University of Bristol) and maintained at the permissive
temperature of 33 C in RPMIþGlutaMAX-I (Gibco) supplemented with 10%
fetal bovine serum, penicillin (50 IUml 1)/streptomycin (50mgml 1) and
insulin–transferrin–selenium-X. To differentiate podocytes, they were cultured at
37 C for 14 days. The FAT1-speciﬁc and control scrambled short interfering RNAs
(siRNAs) were purchased from Dharmacon. siRNAs were transfected into
podocytes using Lipofectamine RNAiMAX (Invitrogen). Mouse kidney collecting
duct IMCD3 cells were obtained from the ATCC (CRL-2123) and cultured
in DMEM/F12 with 10% fetal bovine serum and penicillin (50 IUml 1)/
streptomycin (50 mgml 1). To achieve stable knockdown of FAT1, IMCD3 cells
were transducted with lentivirus, which contained shRNAs. The target sequences of
siRNAs and shRNAs used in this study are in Supplementary Table 2. The shRNA-
stable IMCD3 cells were selected and maintained with 8 mgml 1 puromycin.
Human ﬁbroblasts were grown in DMEM supplemented with 15% FBS, penicillin
(50 IUml 1)/streptomycin (50 mgml 1) and non-essential amino acids
(Invitrogen). Rho/Rac/Cdc42 activator I and Rac/Cdc42 activator II were
purchased from the Cytoskeleton, Inc.
Lentiviral overexpression. The coding sequence of CDC42-T17N was subcloned
to pLenti-CMV-Blast vector (Addgene plasmid #17451)64. For overexpression in
differentiated cultured podocytes, HEK293T cells were transfected with pLenti-
CMV-Blast-CDC42-T17N and lentiviral packaging vectors, pRSV-Rev, pMDLg/
pRRE and pMD2.G. The lentivirus-contacting medium was collected after
48 h and podocytes were infected on day 12 of differentiation with 8 mgml 1
polybrene-containing virus media. Podocytes were used for migration assay
for 72 h after infection.
Immunoblotting and GST pull-down assay. These experiments were performed
as described previously65. Anti-acetylated-a-tubulin (acetyal K40), Anti-b-actin
(AC-15) (Abcam), anti-Rac1 (102/Rac1), anti-Cdc42 (44/CDC42), anti-b-catenin
(14/Beta-Catenin) (BD Transduction Laboratories), anti-RhoA (26C4) (Santa Cruz
Biotechnology) and CEP164 (13) (Sigma-Aldrich) were purchased from
commercial sources. The FAT1–GST antibody, which was generated against
C-terminal 385 aa of mouse FAT1, was previously described by Moeller et al40. All
of the antibodies were used at 1:1,000 for immunoblotting. Uncropped scans of the
western blots are shown in Supplementary Fig. 8.
Migration assay. Real-time migration assay was performed using the
xCELLigence system (ACEA Biosciences) in CIM-plate 16 according to the
manufacturer’s instruction. Brieﬂy, 4 104 cells of ﬁbroblasts, cultured human
podocytes or IMCD3 were plated in serum-free media in the upper chamber.
The lower chambers were with 10% FBS for chemoattraction or with serum-free
media. The obtained data were analysed using the RTCA software. Results are
presented as the time versus cell index curve.
Spheroid assay. IMCD3 cells were trypsinized and resuspended cells were then
mixed 1:1 with growth factor-depleted matrigel (BD Bioscience). This mixture was
then moved to the well of a Nunc Lab-Tek II chambered coverglass (Thermo
Fisher) and allowed to polymerize (45min to 1 h) at 37 C. Once the matrigel was
fully solidiﬁed, warm medium was added drop-wise to the matrix until covered.
After 72 h, the cells had formed spheroids with visible cleared lumens. The
matrigels were then ﬁxed in fresh 4% PFA for 30min at room temperature and
subsequently permeabilized for 15min in gelatin-dissolving PBS and 0.5% Triton
X-100. The primary antibodies (Anti-acetylated-a-tubulin 1:2,000 and b-catenin,
1:500) were incubated at 4 C overnight. Fluorescent images were obtained with a
Leica SP5X laser scanning microscope.
Fluorescence-based cell–cell adhesion assay. This assay was performed as
described previously43. Fibroblasts or cultured human podocytes were resuspended
at 1 106 cells per ml in serum-free medium supplemented with 5 mM calcein AM
and incubated at 37 C for 30min. Cells were washed twice with serum-free
medium, and 1 105 cells were added to microplate wells containing conﬂuent
(unlabelled) cells. Calcein-labelled cells were allowed to adhere for 45min at 37 C.
Non-adherent calcein-labelled cells were washed away with medium, and PBS
was added to each well. Fluorescence was measured at an absorbance of 494 nm
and emission of 517 nm using a SpectraMax Multilabel Microplate Reader
(Molecular Devices).
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